Reddy, Chintam Nagendra, Alhamza, Hussam, Chourey, Shishir, Ye, Qiuji, Gore, Vivek, Cossette, Chantal, Gravel, Sylvie, Slobodchikova, Irina, Vuckovic, Dajana, Rokach, Joshua and Powell, William S. (2018) Metabolism and pharmacokinetics of a potent N -acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys. European Journal of Pharmaceutical Sciences . pp. 1-59. ISSN 09280987 (In Press)
Preview |
Text (application/pdf)
6MBvuckovic-pharmaceutical-sciences-2018.pdf - Accepted Version Available under License Spectrum Terms of Access. |
Official URL: http://dx.doi.org/10.1016/j.ejps.2018.01.021
Abstract
We previously identified the indole 264 as a potent in vitro antagonist of the human OXE receptor that mediates the actions of the powerful eosinophil chemoattractant 5-oxo-ETE. No antagonists of this receptor are currently commercially available or are being tested in clinical studies. The lack of a rodent ortholog of the OXE receptor has hampered progress in this area because of the unavailability of commonly used mouse or rat animal models. In the present study, we examined the feasibility of using the cynomolgus monkey as an animal model to investigate the efficacy of orally administered 264 in future in vivo studies. We first confirmed that 264 is active in monkeys by showing that it is a potent inhibitor of 5-oxo-ETE-induced actin polymerization and chemotaxis in granulocytes. The major microsomal metabolites of 264 were identified by cochromatography with authentic chemically synthesized standards and LC-MS/MS as its ω2-hydroxy and ω2-oxo derivatives, formed by ω2-oxidation of its hexyl side chain. Small amounts of ω1-oxidation products were also identified. None of these metabolites have substantial antagonist potency. High levels of 264 appeared rapidly in the blood following oral administration to both rats and monkeys, and declined to low levels by 24 h. As with microsomes, its major plasma metabolites in monkeys were ω2-oxidation products. We conclude that the monkey is a suitable animal model to investigate potential therapeutic effects of 264. This, or a related compound with diminished susceptibility to ω2-oxidation, could be a useful therapeutic agent in eosinophilic disorders such as asthma.
| Divisions: | Concordia University > Faculty of Arts and Science > Chemistry and Biochemistry |
|---|---|
| Item Type: | Article |
| Refereed: | Yes |
| Authors: | Reddy, Chintam Nagendra and Alhamza, Hussam and Chourey, Shishir and Ye, Qiuji and Gore, Vivek and Cossette, Chantal and Gravel, Sylvie and Slobodchikova, Irina and Vuckovic, Dajana and Rokach, Joshua and Powell, William S. |
| Journal or Publication: | European Journal of Pharmaceutical Sciences |
| Date: | 12 January 2018 |
| Funders: |
|
| Digital Object Identifier (DOI): | 10.1016/j.ejps.2018.01.021 |
| Keywords: | 5-Oxo-ETE; OXE receptor antagonist; Eicosanoids; 5-Lipoxygenase products; Eosinophils; Drug metabolism |
| ID Code: | 983414 |
| Deposited By: | Danielle Dennie |
| Deposited On: | 19 Jan 2018 14:21 |
| Last Modified: | 10 Apr 2019 00:00 |
References:
M. Bäck, W.S. Powell, S.E. Dahlén, J.M. Drazen, J.F. Evans, C.N. Serhan, T. Shimizu, T. Yokomizo, G.E. Rovati Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7 Brit. J. Pharmacol., 171 (2014), pp. 3551–3574M.B. Bailie, T.J. Standiford, L.L. Laichalk, M.J. Coffey, R. Strieter, M. Peters-Golden Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities J. Immunol., 157 (1996), pp. 5221–5224
S. Chourey, Q. Ye, C.N. Reddy, C. Cossette, S. Gravel, M. Zeller, I. Slobodchikova, D. Vuckovic, J. Rokach, W.S. Powell In vivo alpha-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys Biochem. Pharmacol., 138 (2017), pp. 107–118
K.F. Chung Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies J. Intern. Med., 279 (2016), pp. 192–204
C. Cossette, S. Gravel, C.N. Reddy, V. Gore, S. Chourey, Q. Ye, N.W. Snyder, C.A. Mesaros, I.A. Blair, J.P. Lavoie, C.R. Reinero, J. Rokach, W.S. Powell Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes Biochem. Pharmacol., 96 (2015), pp. 247–255
C. Cossette, S. Chourey, Q. Ye, C. Nagendra Reddy, V. Gore, S. Gravel, I. Slobodchikova, D. Vuckovic, J. Rokach, W.S. Powell Pharmacokinetics and metabolism of selective oxoeicosanoid (OXE) receptor antagonists and their effects on 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE)-induced granulocyte activation in monkeys J. Med. Chem., 59 (2016), pp. 10127–10146
M.J. Dallaire, C. Ferland, N. Page, S. Lavigne, F. Davoine, M. Laviolette Endothelial cells modulate eosinophil surface markers and mediator release Eur. Respir. J., 21 (2003), pp. 918–924
V. Gore, P. Patel, C.T. Chang, S. Sivendran, N. Kang, Y.P. Ouedraogo, S. Gravel, W.S. Powell, J. Rokach 5-Oxo-ETE receptor antagonists J. Med. Chem., 56 (2013), pp. 3725–3732
V. Gore, S. Gravel, C. Cossette, P. Patel, S. Chourey, Q. Ye, J. Rokach, W.S. Powell Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists J. Med. Chem., 57 (2014), pp. 364–377
M. Iikura, M. Suzukawa, M. Yamaguchi, T. Sekiya, A. Komiya, C. Yoshimura-Uchiyama, H. Nagase, K. Matsushima, K. Yamamoto, K. Hirai 5-Lipoxygenase products regulate basophil functions: 5-oxo-ETE elicits migration, and leukotriene B(4) induces degranulation J. Allergy Clin. Immunol., 116 (2005), pp. 578–585
J.B. Johnston, H. Ouellet, L.M. Podust, P.R.O. de Montellano Structural control of cytochrome P450-catalyzed omega-hydroxylation Arch. Biochem. Biophys., 507 (2011), pp. 86–94
C.E. Jones, S. Holden, L. Tenaillon, U. Bhatia, K. Seuwen, P. Tranter, J. Turner, R. Kettle, R. Bouhelal, S. Charlton, N.R. Nirmala, G. Jarai, P. Finan Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils Mol. Pharmacol., 63 (2003), pp. 471–477
A.B. Kay Studies on eosinophil leucocyte migration. II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes Clin. Exp. Immunol., 7 (1970), pp. 723–737
A. Langlois, F. Chouinard, N. Flamand, C. Ferland, M. Rola-Pleszczynski, M. Laviolette Crucial implication of protein kinase C (PKC)-delta, PKC-zeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils J. Leukoc. Biol., 85 (2009), pp. 656–663
J.Å. Lindgren, G. Hansson, H.E. Claesson, B. Samuelsson Formation of novel biologically active leukotrienes by omega- oxidation in human leukocyte preparations Adv. Prostaglandin Thromboxane Leukot. Res., 9 (1982), pp. 53–60
C.N. McBrien, A. Menzies-Gow The biology of eosinophils and their role in asthma Front. Med. (Lausanne), 4 (93) (2017)
G. Monneret, S. Gravel, M. Diamond, J. Rokach, W.S. Powell Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor Blood, 98 (2001), pp. 1942–1948
W.S. Powell Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica Prostaglandins, 20 (1980), pp. 947–957
W.S. Powell Properties of leukotriene B4 20-hydroxylase from polymorphonuclear leukocytes J. Biol. Chem., 259 (1984), pp. 3082–3089
W.S. Powell Precolumn extraction and reversed-phase high-pressure liquid chromatography of prostaglandins and leukotrienes Anal. Biochem., 164 (1987), pp. 117–131
W.S. Powell, F. Gravelle Metabolism of arachidonic acid by peripheral and elicited rat polymorphonuclear leukocytes. Formation of 18- and 19-oxygenated dihydro metabolites of leukotriene B4 J. Biol. Chem., 265 (1990), pp. 9131–9139
W.S. Powell, J. Rokach The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor Prog. Lipid Res., 52 (2013), pp. 651–665
W.S. Powell, S. Solomon Formation of 20-hydroxyprostaglandins by lungs of pregnant rabbits J. Biol. Chem., 253 (1978), pp. 4609–4616
W.S. Powell, F. Gravelle, S. Gravel Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes J. Biol. Chem., 267 (1992), pp. 19233–19241
W.S. Powell, D. Chung, S. Gravel 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration J. Immunol., 154 (1995), pp. 4123–4132
W.S. Powell, R.J. MacLeod, S. Gravel, F. Gravelle, A. Bhakar Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils J. Immunol., 156 (1996), pp. 336–342
W.S. Powell, L. Wang, S.P. Khanapure, S. Manna, J. Rokach High-pressure liquid chromatography of oxo-eicosanoids derived from arachidonic acid Anal. Biochem., 247 (1997), pp. 17–24
C.N. Reddy, Q.J. Ye, S. Chourey, S. Gravel, W.S. Powell, J. Rokach Stereoselective synthesis of two highly potent 5-oxo-ETE receptor antagonists Tetrahedron Lett., 56 (2015), pp. 6896–6899
D. Robinson, M. Humbert, R. Buhl, A.A. Cruz, H. Inoue, S. Korom, N.A. Hanania, P. Nair Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications Clin. Exp. Allergy, 47 (2017), pp. 161–175
S. Sarveswaran, J. Ghosh OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells Cancer Lett., 336 (2013), pp. 185–195
G.J. Sturm, R. Schuligoi, E.M. Sturm, J.F. Royer, D. Lang-Loidolt, H. Stammberger, R. Amann, B.A. Peskar, A. Heinemann 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils J. Allergy Clin. Immunol., 116 (2005), pp. 1014–1019
Repository Staff Only: item control page
Download Statistics
Download Statistics